Biotech

Big investment, tiny particles and a giant leap for BNL

BY MICHAEL FAIRLIE // Brookhaven National Laboratory is stepping up its electromicroscopy game, in a big way. The fiscal year 2017 New York State budget includes $15 million for the Upton laboratory to purchase and install a cryo-electron microscope, which will work in tandem with the National Synchrotron Light Source II, the world’s brightest synchrotron light source. The Cryo-EM will be the backbone of BNL’s new Long Island Facility for Electromicroscopy, a national user facility…

Read More

Fighting forced labor, Applied DNA forms cotton club

By GREGORY ZELLER // So, where does your cotton come from? Applied DNA Sciences would like you to know. Adding to its portfolio of crimefighting products and services, the Stony Brook-based biotech has identified lead genetic markers unique to cotton cultivars – produced intentionally by genetic breeding – grown in Uzbekistan, where forced human labor is used to harvest the fluffy fiber. Now, the anti-counterfeiting and product-authentication specialist is “seeking out partners” in an effort…


Scythian, U of M concussion study hits the jack-pot

By GREGORY ZELLER // A Calgary-based R&D firm with strong Long Island ties has swung an eight-figure financing deal, lighting up a major study pitting cannabinoids against concussions. Scythian Biosciences Inc. – owned by owned by Great Neck investment banker Jonathan Gilbert, who partners in fitness-nutrition enterprise Decision Nutrition with his wife, Keren Gilbert, among other ventures – and the University of Miami stand ready with a planned five-year, $16 million study of cannabinoid-based methods…


GE brings good things to bioelectronics research

By GREGORY ZELLER // General Electric is giving the Feinstein Institute for Medical Research a bioelectronic jolt. The Feinstein Institute, R&D mecca of the Northwell Health system, announced a new “strategic alliance” Tuesday with GE Ventures, the multinational conglomerate’s New Jersey-based business-licensing and equity arm. While no financial terms were disclosed, Northwell Health did note an “investment” that will help the Feinstein Institute’s evolving Center for Bioelectronic Medicine “continue its work in discovering, developing and…


New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…


Codagenix: Flu can mutate, but it can’t hide

By GREGORY ZELLER // In a potentially huge breakthrough in the struggle against seasonal influenza mutations, Codagenix Inc. is preparing to release data demonstrating “multi-season efficacy” for its frontline flu vaccine – meaning the vaccine could prevent flu-related sicknesses even after the virus mutates. According to the Farmingdale-based clinical-stage startup, in multiple studies involving pigs and ferrets, CodaVax-H1N1 – Codagenx’s live-attenuated Influenza A vaccine – induced “a robust immune response to multiple seasonal strains of…


Still cutting its teeth, Traverse set for stellar 2017

By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may ultimately pale compared to what’s shaping up as a potentially enormous 2017 for the Stony Brook biotech and its flagship pharmaceutical. Fueled primarily by a $1.32 million Phase II Small Business Technology Transfer award granted by the National Institutes of Health in August to the…